Syndax Pharmaceuticals Priced, Nasdaq: SNDX

Developing a therapy that enhances checkpoint immuno-oncology drugs.

Industry: Health Care

Latest Trade: $9.83 0.00 (0.0%)

First Day Return: +0.1%

Return from IPO: -18.1%

Industry: Health Care

We are a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with our initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple negative breast cancer. Entinostat is our oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body’s immune response to tumors. The favorable safety profile of entinostat has been demonstrated in clinical trials in more than 900 cancer patients. We are currently evaluating entinostat in combination with Keytruda (pembrolizumab) in a Phase 1b/2 clinical trial for non-small cell lung cancer and melanoma, and we plan to initiate a Phase 1b/2 clinical trial for entinostat in combination with atezolizumab in TNBC in the first half of 2016 and a Phase 1b/2 clinical trial for entinostat in combination with avelumab in ovarian cancer in the second half of 2016. We believe that, based on its mechanism of action, entinostat may have broad applications in additional tumor types, including head and neck, bladder and renal cell, which are immuno-responsive, or sensitive to immunotherapy.
more less
IPO News for Syndax Pharmaceuticals
more
IPO Data
IPO File Date 01/04/2016
Offer Price $12.00
Price Range $14.00 - $16.00
Offer Shares (mm) 4.4
Deal Size ($mm) $53
IPO Data
IPO Date 03/02/2016
Offer Price $12.00
Price Range $14.00 - $16.00
Offer Shares (mm) 4.4
Deal Size ($mm) $53
Underwriters
more
Company Data
Headquarters Waltham, MA
Founded 2005
Employees 17
Website www.syndax.com